Tyndall M - Search Results

1

Recent incarceration linked to cutaneous injection-related infections among active injection drug users in a Canadian setting.

Milloy MJ, Wood E, Lloyd-Smith E, Grafstein E, Tyndall M, Montaner J, Kerr T. Milloy MJ, et al. Among authors: tyndall m. J Community Health. 2010 Dec;35(6):660-6. doi: 10.1007/s10900-010-9269-y. J Community Health. 2010. PMID: 20364303

2

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Wood E, et al. CMAJ. 2003 Sep 30;169(7):656-61. CMAJ. 2003. PMID: 14517122 Free PMC article.

3

Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.

Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW. Wood E, et al. CMAJ. 2004 Sep 28;171(7):731-4. doi: 10.1503/cmaj.1040774. CMAJ. 2004. PMID: 15451834 Free PMC article.

4

Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use.

Collins CL, Kerr T, Kuyper LM, Li K, Tyndall MW, Marsh DC, Montaner JS, Wood E. Collins CL, et al. Among authors: tyndall mw. J Urban Health. 2005 Jun;82(2):276-84. doi: 10.1093/jurban/jti051. Epub 2005 May 4. J Urban Health. 2005. PMID: 15872188 Free PMC article.

5

A description of a peer-run supervised injection site for injection drug users.

Kerr T, Oleson M, Tyndall MW, Montaner J, Wood E. Kerr T, et al. Among authors: tyndall mw. J Urban Health. 2005 Jun;82(2):267-75. doi: 10.1093/jurban/jti050. Epub 2005 May 4. J Urban Health. 2005. PMID: 15872193 Free PMC article.

6

Do supervised injecting facilities attract higher-risk injection drug users?

Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JS, Kerr T. Wood E, et al. Am J Prev Med. 2005 Aug;29(2):126-30. doi: 10.1016/j.amepre.2005.04.011. Am J Prev Med. 2005. PMID: 16005809

7

Requiring help injecting independently predicts incident HIV infection among injection drug users.

O'Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, Wood E. O'Connell JM, et al. Among authors: tyndall mw. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):83-8. doi: 10.1097/01.qai.0000157006.28535.ml. J Acquir Immune Defic Syndr. 2005. PMID: 16123687

8

Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users.

Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, Montaner JS, Hogg RS. Wood E, et al. J Infect. 2006 Apr;52(4):233-6. doi: 10.1016/j.jinf.2005.07.008. Epub 2005 Sep 19. J Infect. 2006. PMID: 16169594

9

Attendance, drug use patterns, and referrals made from North America's first supervised injection facility.

Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E. Tyndall MW, et al. Drug Alcohol Depend. 2006 Jul 27;83(3):193-8. doi: 10.1016/j.drugalcdep.2005.11.011. Epub 2005 Dec 13. Drug Alcohol Depend. 2006. PMID: 16356659

10

Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.

Lloyd-Smith E, Brodkin E, Wood E, Kerr T, Tyndall MW, Montaner JS, Hogg RS. Lloyd-Smith E, et al. AIDS. 2006 Feb 14;20(3):445-50. doi: 10.1097/01.aids.0000206508.32030.92. AIDS. 2006. PMID: 16439879

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

289 results

Search Page

Filters